Positive News SentimentPositive NewsNASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis $3.02 -0.03 (-0.98%) As of 11/16/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Galectin Therapeutics Stock (NASDAQ:GALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Galectin Therapeutics alerts:Sign Up Key Stats Today's Range$2.93▼$3.2150-Day Range$2.97▼$4.1452-Week Range$2.03▼$7.13Volume231,993 shsAverage Volume196,727 shsMarket Capitalization$198.90 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment. The company was previously known as Pro-Pharmaceuticals before adopting the Galectin Therapeutics name. Its work is centered on drug research and clinical development rather than the sale of marketed medicines.AI Generated. May Contain Errors. Read More Galectin Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreGALT MarketRank™: 2.01532311792 of 5 starsGalectin Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 666th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingGalectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialGalectin Therapeutics has a consensus price target of $11.00, representing about 264.2% upside from its current price of $3.02.Amount of Analyst CoverageGalectin Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Galectin Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.00% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 46.26, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently decreased by 1.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment1.60 News SentimentGalectin Therapeutics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Galectin Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders53.00% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GALT Stock News HeadlinesGalectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 16 at 2:13 PM | marketscreener.comMGalectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business UpdateNovember 16 at 8:00 AM | globenewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Galectin Therapeutics (GALT) Set to Release Earnings on FridayNovember 6, 2026 | americanbankingnews.comGalectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026November 5, 2026 | globenewswire.comGalectin Therapeutics Inc GALTNovember 3, 2026 | morningstar.comMGalectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is CriticalOctober 6, 2026 | seekingalpha.comGalectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026October 6, 2026 | globenewswire.comSee More Headlines GALT Stock Analysis - Frequently Asked Questions How have GALT shares performed this year? Galectin Therapeutics' stock was trading at $4.16 at the beginning of the year. Since then, GALT stock has decreased by 27.4% and is now trading at $3.02. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Monday, November, 16th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Who are Galectin Therapeutics' major shareholders? Top institutional shareholders of Galectin Therapeutics include State Street Corp (1.22%), Marshall Wace LLP (0.71%), Commonwealth Equity Services LLC (0.70%) and Horizon Kinetics Asset Management LLC (0.06%). Insiders that own company stock include James C Czirr, Fund LP 10X, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Jack W Callicutt, Harold H Shlevin and Khurram Jamil. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Viking Therapeutics (VKTX), Walt Disney (DIS), Pfizer (PFE), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Ford Motor (F). Company Calendar Today11/16/2026Last Earnings11/16/2026AGM 202612/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 6 days, GALT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GALT CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees9Year Founded2001Price Target and Rating Average Price Target for Galectin Therapeutics$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+264.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.84 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-176.83% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.99) per share Price / Book-1.52Miscellaneous Outstanding Shares65,860,000Free Float30,953,000Market Cap$198.90 million OptionableOptionable Beta0.53 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:GALT) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.